A supplement to Skin & Allergy News.
This educational supplement was supported by a restricted educational grant from 3M Pharmaceuticals.
The presentations took place at a symposium held on November 19, 2004 in Florence, Italy.
To view the supplement, click the image above.
Topics Highlights/Faculty
Introduction
Professor Alberto Giannetti, MD, Chair
Professor of Dermatology
Department of Dermatology and Director of the Specializing School in Dermatology and Venereology
University of Modena
Italy
Nothing to disclose.
Professor Wolfram Sterry, MD, Co-Chair
Professor, Department of Dermatology Chair
Charité University Hospital
Humboldt University
Berlin, Germany
Received funding for clinical grants from 3M, Coley Pharmaceutical Group, Inc., and Shire Pharmaceuticals Group plc.
The Histopathology of Nonmelanoma Skin Caners: Overview of Recent Findings
Professor Helmut Kerl, MD
Professor and Chairman
Department of Dermatology
Medical University of Graz
Austria
Consultant to 3M.
The Emerging Potential of Immune Response Modifier Therapy in Superficial Skin Cancers
Professor Reinhard Dummer, MD
Professor of the Department of Dermatology
University Hospital of Zurich
Switzerland
Consultant to 3M Pharmaceuticals. He discusses the investigational use of imiquimod in treating mycosis fungoides, cutaneous T-cell lymphomas, and lentigo maligna.
The Role of Imiquimod in the Treatment of BCC: Clinical Evidence
Professor Nicole Basset-Séguin, MD, PhD
Professor in Dermatology
Hôpital Saint-Louis
Paris, France
Nothing to disclose.
Illuminating the Mode of Action of Immune Response Modifier Therapy in Superficial Skin Cancers
Professor Dr med Eggert Stockfleth
Head of Derm-Oncology Department
Clinic for Dermatology, Venereology and Allergy
University School of Medicine, Charité
Berlin, Germany
Discusses the investigational use of immune response modifiers as oral therapy in patients with hepatitis infections and as an adjuvant for vaccines.
Copyright © 2005 by International Medical News Group